Satellos Bioscience Announces Significant Increase in Muscle Size and Function in Duchenne Muscular Dystrophy Disease Model
- 40% increase in muscle size compared to control mice
- 25% increase in muscle force, approaching levels seen in normal mice
Toronto, Ontario--(Newsfile Corp. - February 6, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, is pleased to announce results from multiple preclinical studies in a disease model of Duchenne muscular dystrophy ("Duchenne"). An updated corporate presentation has been posted to the Company's website (www.satellos.com).
Satellos' proprietary MyoReGenX™ assay platform identified a protein kinase (codenamed "K9") as a potential drug target to modulate polarity in muscle stem cells. Using a known inhibitor of this kinase target as a reference compound for generating Proof of Concept to guide future drug development efforts with its own compounds, Satellos treated Mdx mice, a gold-standard experimental model for studying Duchenne, for a period of two (2) weeks. Drug treated muscles were larger in size than untreated control muscles by an average of 40% and displayed about a 25% increase in ability to generate force, approaching levels seen in normal mice.
"To the best of our knowledge, these pre-clinical results are unprecedented for a small molecule therapeutic approach to treat Duchenne as they represent the first time a small molecule has induced these levels of muscle growth that translate to clear functional benefit -- and so rapidly," said Frank Gleeson, President and CEO of Satellos. "We are so energized by seeing such an effect on regeneration because of the potential it represents for a future treatment to regenerate functional muscle in patients."
Added Dr. Michael Rudnicki, the Company's co-founder and Chief Scientific Officer, "We believe these results continue to solidify our mechanistic approach of targeting the restoration of muscle regeneration through modulating muscle stem cell polarity."
Continued Dr. Phil Lambert, Chief Technical Officer with overall responsibility for drug development at Satellos, "We are very excited by this data set particularly considering that the reference compound was not specifically designed for the treatment of a muscle disease. These results provide an excellent experimental roadmap for the continued development of SAT-3153, a proprietary compound specifically designed by Satellos scientists to modulate polarity in muscle stem cells."
Satellos believes that a dysfunction in the normal process of stem cell polarity in response to muscle damage represents a previously unrecognized root cause of Duchenne. The goal of correcting polarity in Duchenne is to restore the body's innate ability to regenerate muscle in response to the ongoing damage experienced by people living with Duchenne. SAT-3153 has been designated by Satellos as its lead drug candidate and the Company is pursuing pre-IND development activities.
About Satellos Bioscience Inc.
Satellos is a biotechnology company dedicated to developing life-changing medicines to treat degenerative muscle conditions. Our scientists discovered what we believe to be a previously unrecognized root cause of skeletal muscle degeneration. One which has the potential to transform how muscle disorders are treated. Our scientific founder, Dr. Michael Rudnicki, is a thought leader who discovered and has shown how muscle stem cells regulate muscle repair and growth throughout life. He has shown how defects in a process known as stem cell "polarity", which controls how muscle stem cells divide to create muscle progenitor cells, lead to a failure of muscle regeneration in Duchenne and potentially other muscle disorders. As a result of this ongoing inability to produce sufficient numbers of new muscle cells, the muscles of people living with Duchenne are unable to keep up with and repair the continuous and accumulating damage their muscles experience. Satellos' lead program is focused on developing an oral therapeutic drug (i.e., a pill) intended to correct muscle stem cell polarity and restore the body's innate muscle repair and regeneration process. We believe our unique therapeutic approach represents a potential disease modifying treatment for Duchenne and other dystrophies, offering new hope to patients. To expand our programs to other degenerative muscle conditions or disorders, Satellos has created a proprietary discovery platform, MyoReGenX™, which we utilize to identify disease situations where deficits in muscle stem cell polarity and regeneration occur and are amenable to therapeutic treatment. For more information about or to discuss potential collaborations with Satellos concerning our discovery platform and therapeutic candidates or our subsidiary Amphotericin B Technologies Inc., please contact Ryan Mitchell, Ph.D., Director - Business Development at firstname.lastname@example.org or visit Satellos.com.
Communications at Satellos Bioscience Inc.
Notice on forward-looking statements:
This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding Satellos and its business, which may include, but are not limited to, statements regarding the anticipated benefits to patients from a small molecule treatment for Duchenne; the general benefits of modulating stem cell polarity by administering small molecule drugs; its/their prospective impact on Duchenne patients and muscle regeneration generally; the utility of regenerating muscle by modulating polarity; and Satellos' technologies and drug development plans. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, occurrences or developments, are "forward-looking information or statements". Often but not always, forward-looking information or statements can be identified by the use of words such as "shall", "intends", "anticipate", "believe", "plan", "expect", "intend", "estimate", "anticipate", "potential", "prospective" or any variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "might", "can", "could", "would" or "will" be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks relating to the pharmaceutical and bioscience industry, general market conditions and equity markets, economic factors and management's ability to manage and to operate the business of the Company generally. Although Satellos has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Satellos does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.
No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/153705